Skip to main content
Log in

Baclofen and Gamma-Hydroxybutyrate Withdrawal

  • Published:
Neurocritical Care Aims and scope Submit manuscript

Abstract

Introduction

Benzodiazepine treatment of life-threatening gamma-hydroxybutyrate (GHB) withdrawal is frequently unsatisfactory. Animal studies suggest strongly that treatment with GABAB agonists, such as baclofen, will be a more effective strategy.

Methods

A case report from the medical intensive care unit (ICU) of the university tertiary care hospital.

Results

A 61-year-old woman was admitted to the medical ICU for severe withdrawal symptoms from chronic GHB use. This manifested as delirium, tremor, and seizures despite only small decreases in GHB dose and treatment with benzodiazepines. The addition of baclofen allowed the rapid sequential decreases in the GHB dose without seizure or delirium and resulted in long-term improvement of her tremor.

Conclusions

Baclofen, a GABAB agonist, may be a useful agent in the treatment of severe GHB withdrawal.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

g:

Grams

GABA:

Gamma-aminobutyric acid

GHB:

Gamma-hydroxybutyrate

h:

Hours

ICU:

Intensive care unit

mg:

Milligrams

References

  1. Teter CJ, Guthrie SK. A comprehensive review of MDMA, GHB: two common club drugs. Pharmacotherapy 2001;21(12):1486–513.

    Article  PubMed  CAS  Google Scholar 

  2. Miro O, Nogue S, Espinosa G, To-Figueras J, Sanchez M. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol Clin Toxicol 2002;40(2):129–35.

    Article  PubMed  CAS  Google Scholar 

  3. Snead OC III, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med 2005;352(26):2721–32.

    Article  PubMed  CAS  Google Scholar 

  4. Fuller DE, Hornfeldt CS. From club drug to orphan drug: sodium oxybate (Xyrem) for the treatment of cataplexy. Pharmacotherapy 2003;23(9):1205–9.

    Article  PubMed  CAS  Google Scholar 

  5. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005;1(4):391–7.

    Google Scholar 

  6. Poldrugo F, Addolorato G. The role of gamma-hydroxybutyric acid in the treatment of alcoholism: from animal to clinical studies. Alcohol Alcohol 1999;34(1):15–24.

    PubMed  CAS  Google Scholar 

  7. UCB and Jazz Pharmaceuticals Announce Expansion of Xyrem License to Include Fibromyalgia Syndrome (2006). http://www.jazzpharma.com/news.php?id=32.

  8. Addolorato G, Castelli E, Stefanini GF, Casella G, Caputo F, Marsigli L, Bernardi M, Gasbarrini G. An open multicentric study evaluating 4-hydroxybutyric acid sodium salt in the medium-term treatment of 179 alcohol dependent subjects. GHB Study Group. Alcohol Alcohol 1996;31(4):341–5.

    PubMed  CAS  Google Scholar 

  9. Freese TE, Miotto K, Reback CJ. The effects and consequences of selected club drugs. J Subst Abuse Treat 2002;23(2):151–6.

    Article  PubMed  Google Scholar 

  10. Gallimberti L, Spella MR, Soncini CA, Gessa GL. Gamma-hydroxybutyric acid in the treatment of alcohol and heroin dependence. Alcohol 2000;20(3):257–62.

    Article  PubMed  CAS  Google Scholar 

  11. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001;37(2):147–53.

    Article  PubMed  CAS  Google Scholar 

  12. Project GHB (2002). http://www.projectghb.org/addiction/addiction.htm.

  13. McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004;75(1):3–9.

    Article  PubMed  CAS  Google Scholar 

  14. Snead OC III, Liu CC. GABAA receptor function in the gamma-hydroxybutyrate model of generalized absence seizures. Neuropharmacology 1993;32(4):401–9.

    Article  PubMed  CAS  Google Scholar 

  15. Goodwin AK, Griffiths RR, Brown PR, Froestl W, Jakobs C, Gibson KM, Weerts EM. Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons. Psychopharmacology (Berl) 2006;189(1):71–82.

    Article  CAS  Google Scholar 

  16. Wu Y, Ali S, Ahmadian G, Liu CC, Wang YT, Gibson KM, Calver AR, Francis J, Pangalos MN, Carter Snead O III. Gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB receptor (GABABR) binding sites are distinctive from one another: molecular evidence. Neuropharmacology 2004;47(8):1146–56.

    Article  PubMed  CAS  Google Scholar 

  17. Gervasi N, Monnier Z, Vincent P, Paupardin-Tritsch D, Hughes SW, Crunelli V, Leresche N. Pathway-specific action of gamma-hydroxybutyric acid in sensory thalamus and its relevance to absence seizures. J Neurosci 2003;23(36):11469–78.

    PubMed  CAS  Google Scholar 

  18. Hechler V, Ratomponirina C, Maitre M. Gamma-hydroxybutyrate conversion into GABA induces displacement of GABAB binding that is blocked by valproate and ethosuximide. J Pharmacol Exp Ther 1997;281(2):753–60.

    PubMed  CAS  Google Scholar 

  19. Bormann J, Hamill OP, Sakmann B. Mechanism of anion permeation through channels gated by glycine and gamma-aminobutyric acid in mouse cultured spinal neurones. J Physiol 1987;385:243–86.

    PubMed  CAS  Google Scholar 

  20. Smith SM, Zorec R, McBurney RN. Conductance states activated by glycine and GABA in rat cultured spinal neurones. J Membr Biol 1989;108(1):45–52.

    Article  PubMed  CAS  Google Scholar 

  21. Cruz HG, Ivanova T, Lunn ML, Stoffel M, Slesinger PA, Luscher C. Bi-directional effects of GABA(B) receptor agonists on the mesolimbic dopamine system. Nat Neurosci 2004;7(2):153–9.

    Article  PubMed  CAS  Google Scholar 

  22. Kaupmann K, Cryan JF, Wellendorph P, Mombereau C, Sansig G, Klebs K, Schmutz M, Froestl W, van der Putten H, Mosbacher J, et al. Specific gamma-hydroxybutyrate-binding sites but loss of pharmacological effects of gamma-hydroxybutyrate in GABA(B)(1)-deficient mice. Eur J Neurosci 2003;18(10):2722–30.

    Article  PubMed  Google Scholar 

  23. Smith MA, Gergans SR, Lyle MA. The motor-impairing effects of GABA(A) and GABA(B) agonists in gamma-hydroxybutyrate (GHB)-treated rats: cross-tolerance to baclofen but not flunitrazepam. Eur J Pharmacol 2006;552(1–3):83–9.

    Article  PubMed  CAS  Google Scholar 

  24. Perez E, Chu J, Bania T. Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal. Ann Emerg Med 2006;48(2):219–20.

    Article  PubMed  Google Scholar 

  25. Chew G, Fernando A III. Epileptic seizure in GHB withdrawal. Australas Psychiatry 2004;12(4):410–11.

    Article  PubMed  Google Scholar 

  26. Quang LS, Desai MC, Kraner JC, Shannon MW, Woolf AD, Maher TJ. Enzyme and receptor antagonists for preventing toxicity from the gamma-hydroxybutyric acid precursor 1,4-butanediol in CD-1 mice. Ann NY Acad Sci 2002;965:461–72.

    Article  PubMed  CAS  Google Scholar 

  27. Mullins ME, Fitzmaurice SC. Lack of efficacy of benzodiazepines in treating gamma-hydroxybutyrate withdrawal. J Emerg Med 2001;20(4):418–20.

    Article  PubMed  CAS  Google Scholar 

  28. Turner MR, Gainsborough N. Neuroleptic malignant-like syndrome after abrupt withdrawal of baclofen. J Psychopharmacol 2001;15(1):61–3.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Stephen M. Smith.

Rights and permissions

Reprints and permissions

About this article

Cite this article

LeTourneau, J.L., Hagg, D.S. & Smith, S.M. Baclofen and Gamma-Hydroxybutyrate Withdrawal. Neurocrit Care 8, 430–433 (2008). https://doi.org/10.1007/s12028-008-9062-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12028-008-9062-2

Keywords

Navigation